Heme Oxygenase-1 as a novel therapeutic target in HIV-mediated neurodegeneration
Heme Oxygenase-1 as a novel therapeutic target in HIV-mediated neurodegeneration
批准号:
9100937
负责人:
Alexander J Gill
金额:
$3.02万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-01 至 2017-05-31
关键词:
Anti-Inflammatory AgentsAnti-inflammatoryAntioxidantsBehavioralBlood - brain barrier anatomyBrainBrain regionCD4 Positive T LymphocytesChronic Kidney FailureClinical ResearchCognitiveDataDegradation PathwayDiseaseDisease MarkerDisease ProgressionEnzymesEstersExcitatory NeurotoxinsFumaratesFumaric acidGlutamatesHIVHIV InfectionsHIV-associated neurocognitive disorderHemeImmuneImpairmentIn VitroIndividualInflammationInflammatoryInfluenzaLesionLymphocyte CountMacrophage ActivationMediatingMicrogliaModelingMotorMultiple SclerosisNerve DegenerationNeurocognitiveNeurocognitive DeficitNeurodegenerative DisordersNeuronal InjuryNeurotoxinsOxidative StressPathway interactionsPatientsPhase III Clinical TrialsPrefrontal CortexProductionPropertyProtein DeficiencyProteinsRelapseResponse ElementsRoleSafetySentinelStrokeTherapeuticTissuesViral Load resultViral PhysiologyWorkantiretroviral therapybrain tissuecerebral atrophycytokineheme oxygenase-1in vitro Modelin vivolung injurymRNA Expressionmacrophagemonocyteneuroinflammationneuron lossneuropathologyneurotoxicitynew therapeutic targetnovelnovel therapeuticsprotein expressionpublic health relevancerepositoryresponsetherapeutic target
中文摘要
描述(由申请人提供):HIV感染导致认知、运动和行为缺陷,统称为HIV相关神经认知障碍(HAND)。尽管抗逆转录病毒治疗,约50%的艾滋病毒患者继续发展为神经认知障碍,确认需要辅助治疗。临床研究表明,HAND神经认知障碍与中枢神经系统巨噬细胞/小胶质细胞活化有关。激活和感染hiv的单核细胞源性巨噬细胞(HIV-MDM)和小胶质细胞通过可溶性因子介导HAND神经病理,包括兴奋性神经毒素,如谷氨酸,诱导神经元损伤。HAND患者脑脊液中谷氨酸水平升高,这与神经认知障碍和脑萎缩的程度有关。鉴定HIV-MDM中调节神经毒素释放的内源性途径,特别是谷氨酸释放,可能为HAND神经退行性变提供重要的治疗靶点。体内氧化应激标志物与HIV+患者的神经认知障碍相关。我们已经明确证明血红素加氧酶-1 (HO-1),哨兵细胞保护性抗氧化反应蛋白,是HIV-MDM神经毒性的关键调节因子。HO-1在HIV-MDM中显著抑制,并与谷氨酸产生和神经毒素释放相关。相反,HO-1在HIV-MDM中的诱导减少了神经毒素的释放,这表明HO-1是HAND的一个新的治疗靶点。我们发现HO-1的表达在HIV阳性患者的前额皮质中降低。这种脑HO-1抑制与执行区神经认知障碍、中枢神经系统病毒载量和巨噬细胞激活相关。我们将在一个扩大的脑区域面板中评估HO-1的区域表达,以确定其与相关神经认知域和HIV疾病进展标志物的相关性。我们还将通过分析HO-1 mRNA和蛋白的表达和稳定性来研究目前未知的HO-1在HIV-MDM中的抑制机制。最后,我们将扩展我们之前的工作,进一步确定HO-1诱导在减少HIV-MDM神经毒素产生方面的治疗潜力。特别是,我们将研究富马酸酯(FAEs),包括富马酸二甲酯(DMF),作为潜在的治疗候选者。DMF通过ARE诱导HO-1,穿过血脑屏障,并在多发性硬化症III期临床试验中显示出减少神经炎症的作用。DMF在MS试验中的安全性和有效性、其抗炎特性和对HO-1的诱导强调了其治疗HAND的潜力。我们假设HIV驱动的HIV阳性患者中枢神经系统中HO-1的抑制驱动巨噬细胞介导的神经退行性变,并且通过fae如DMF逆转这种HO-1缺陷将改善这种神经退行性变。
英文摘要
DESCRIPTION (provided by applicant): HIV infection causes cognitive, motor, and behavioral deficits collectively known as HIV-associated neurocognitive disorders (HAND). Despite antiretroviral therapy, ~50% of HIV patients continue to develop neurocognitive impairment, affirming a need for adjunctive therapy. Clinical studies have shown that neurocognitive impairment in HAND correlates with CNS macrophage/microglia activation. Activated and HIV-infected monocyte-derived macrophages (HIV-MDM) and microglia mediate HAND neuropathology through soluble factors, including excitatory neurotoxins like glutamate, which induce neuronal injury. HAND patients have increased levels of glutamate in their CSF, which correlates with the degree of neurocognitive impairment and brain atrophy. Identification of endogenous pathways that regulate neurotoxin release, particularly glutamate, in HIV-MDM may provide important therapeutic targets for neurodegeneration in HAND. In vivo markers of oxidative stress correlate with neurocognitive impairment in HIV+ patients. We have specifically demonstrated that heme oxygenase-1 (HO-1), the sentinel cytoprotective antioxidant response protein, is a key regulator of HIV-MDM neurotoxicity. HO-1 is strikingly suppressed in HIV-MDM and correlates to glutamate production and neurotoxin release. In contrast, HO-1 induction in HIV-MDM decreases neurotoxin release, suggesting HO-1 as a novel therapeutic target in HAND. We found HO-1 expression to be decreased in the prefrontal cortex of HIV+ patients. This HO-1 suppression in the brain correlates with executive domain neurocognitive impairment, CNS viral load, and macrophage activation. We will evaluate the regional expression of HO-1 in an expanded panel of brain regions to determine correlations to relevant neurocognitive domains and markers of HIV disease progression. We will also investigate the currently unknown mechanism of HO-1 suppression in HIV-MDM through analysis of HO-1 mRNA and protein expression and stability. Lastly, we will expand upon our previous work to further define the therapeutic potential for HO-1 induction in reducing HIV-MDM neurotoxin production. Particularly, we will study the fumaric acid esters (FAEs), including dimethyl fumarate (DMF), as potential therapeutic candidates. DMF induces HO-1 through the ARE, cross the blood brain barrier, and has been shown to decrease neuroinflammation in multiple sclerosis phase III clinical trials. The safety and efficacy of DMF in MS trials, their anti-inflammatory properties, their induction of HO-1 underscore their therapeutic potential in HAND. We hypothesize that HIV-driven suppression of HO-1 in the CNS of HIV+ patients drives macrophage-mediated neurodegeneration and that reversal of this HO-1 deficiency through FAEs such as DMF will ameliorate this neurodegeneration.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1097/coh.0000000000000105
发表时间:
2014-11
期刊:
Current opinion in HIV and AIDS
影响因子:
4.1
作者:
[Chen MF, Gill AJ, Kolson DL]
通讯作者:
Kolson DL
DOI:
10.1007/s11904-014-0210-3
发表时间:
2014-09
期刊:
CURRENT HIV/AIDS REPORTS
影响因子:
4.6
作者:
[Gill, Alexander J., Kolson, Dennis L.]
通讯作者:
Kolson, Dennis L.
Heme Oxygenase-1 as a novel therapeutic target in HIV-mediated neurodegeneration
-
批准号:8731410
-
项目类别:
-
资助金额:$4.61万
-
财政年份:2014
-
负责人:Alexander J Gill
-
依托单位:
Heme Oxygenase-1 as a novel therapeutic target in HIV-mediated neurodegeneration
-
批准号:8932606
-
项目类别:
-
资助金额:$2.98万
-
财政年份:2014
-
负责人:Alexander J Gill
-
依托单位:
海外基金